GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results for GSK
1,640.08
+7.58 (0.46%)
Feb 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 1,619.00 - 1,659.00
52 week 1,355.00 - 1,745.56
Open 1,631.50
Vol / Avg. 6.25M/8.82M
Mkt cap 80.53B*
P/E 88.61
Div/yield 23.00*
EPS 0.19*
Shares 4.91B
Beta     -
Inst. own     -
*GBP
Feb 1, 2017
Q4 2016 GlaxoSmithKline PLC Earnings Release (Estimated)
Nov 29, 2016
GlaxoSmithKline PLC Corporate Analyst Meeting
  

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 4.18% 3.81%
Operating margin 7.84% 9.32%
EBITD margin - 32.04%
Return on average assets 2.16% 1.89%
Return on average equity 163.36% 29.24%
Employees 101,192 -
CDP Score - 100 B

Address

980 Great West Road
BRENTFORD, TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Officers and directors

Emma Walmsley Chief Executive Officer - Designate, Executive Director
Age: 46
Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 51
Simon Dingemans Chief Financial Officer, Executive Director
Age: 52
Moncef Slaoui Chairman - Global Vaccines, Executive Director
Age: 56
Patrick Vallance President - Pharmaceuticals R&D, Executive Director
Roger Connor President - Global Manufacturing & Supply
Abbas Hussain President - Global Pharmaceuticals
Shah Abbas Hussain President - Global Pharmaceuticals
Luke Miels President - Global Pharmaceuticals
Daniel Troy Senior Vice President, General Counsel